PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast - Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease

Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease

07/22/21 • 30 min

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Go online to PeerView.com/YFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses new evidence from ASCO 2021 on the continuing integration of immunotherapy, targeted agents, and novel therapeutics across a wide range of renal cell carcinoma settings. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

Previous Episode

Matthew D. Galsky, MD - New and Emerging Therapeutic Strategies in Bladder Cancer: Updates in Early-Stage Disease and Beyond

Go online to PeerView.com/MHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary oncology discusses new and emerging strategies for the management of patients with bladder cancer. Upon completion of this accredited CE activity, participants should be better able to: Review when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Summarize key findings from pivotal clinical trials on newer therapies, including immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates, across the spectrum of bladder cancer settings, Consider patient-related factors and preferences in the selection of novel therapeutics for the management of bladder cancer, Integrate appropriate strategies to mitigate and manage unique adverse events associated with new immune-, targeted-, and antibody-based treatments for bladder cancer.

Next Episode

undefined - Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM

Vanita R. Aroda, MD - Determining Which Patients Will Benefit From GLP-1 RAs: Applying Guidelines and Evidence to Individualize Treatment Decisions in T2DM

Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.